PHARMACEUTICAL COMPOSITION, COMPOUND, CRYSTALLINE FORM OF THE COMPOUND, AGENTS TO REDUCE BLOOD INDOXYL SULFATE, TO PREVENT OR TREAT A DISEASE CAUSED BY AN INCREASE IN BLOOD INDOXYL SULFATE, TO SLOW DOWN THE TRANSITION TO UNDERSTAND THERAPEUTIC THERAPY AND UNDERSTANDING RUBBER THERAPY. REMAINING KIDNEY FUNCTION IN A PATIENT AFTER TRANSITION TO KIDNEY REPLACEMENT THERAPY, USE OF COMPOUND, AND METHODS TO REDUCE BLOOD INDOXYL SULFATE AND TO PREVENT OR TREAT A DISEASE
KOJI MATSUMOTO,NAOMI TANAKA,TAICHI FUKUNAGA,TSUYOSHI SONEDA,YUJI NAKAMURA
申请号：
BR112019006937
公开号：
BR112019006937A2
申请日:
2017.10.05
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
The present invention addresses the problem of finding a novel drug which has an excellent tryptophanase inhibitory effect, suppresses the production of indoxyl sulfate in the blood to thereby prevent worsening of renal function and thus contributes to the preservation of the kidney. A pharmaceutical composition comprising a compound represented by the formula or a pharmacologically acceptable salt thereof as an active ingredient is provided. [formula 1] (in formula: R1 and R2 are the same or different and represent a C1-C6 alkyl group, etc.； and ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.)a presente invenção trata do problema de encontrar um novo medicamento que tenha um excelente efeito inibidor da triptofanase, suprima a produção de sulfato de indoxila no sangue para assim prevenir o agravamento da função renal e, assim, contribui para a preservação do rim. é provida uma composição farmacêutica que compreende um composto representado pela fórmula ou um sal farmacologicamente aceitável do mesmo como ingrediente ativo. [fórmula 1] (na fórmula: r1 e r2 são iguais ou diferentes e representam um grupo alquila c1-c6, etc.； e ar representa um grupo fenila opcionalmente substituído ou um grupo tienila opcionalmente substituído.)
